Lung cancer MDT — open form

A browser tool for lung cancer MDT preparation using free-text fields.

🔒 Privacy notice.

Use notice.

Meeting

Meeting date

Presenter

Hospital / centre

Patient

Age

Sex

Smoking status

Pack-years

Years since quitting if former smoker

Weight (kg)

Height (cm)

BMI auto-calculated

Comorbidity and medication

Significant comorbidities Previous cancers and surgeries Anticoagulation and immunosuppression drug, indication, pausing

Functional status

WHO / ECOG performance status G8 score geriatric screening, 0 to 17 Performance / exercise capacity

Lung function

FVC value, %, z-score

FEV1 value, %, z-score

DLCO

DLCO/VA (%)

V/Q scan result

Imaging

Baseline diagnostic CT

CT date

CT region

Contrast

Primary lesion and thoracic findings Nodal findings on CT Extrathoracic findings on CT

PET-CT

PET-CT date

PET status

Comparison with CT

PET-CT findings Sites needing confirmation

Brain imaging

Brain imaging date

Brain imaging modality

Contrast

Brain imaging findings

Previous and comparison imaging

Previous CT date

Previous PET-CT date

Other comparison date

Growth / stability / volume doubling time Prior imaging relevance

Radiology review for MDT

Radiology review date

Radiologist present at MDT?

Imaging complete for staging?

Radiology MDT question Radiology conclusion / missing imaging

Other imaging studies method + date + main findings

Pathology

Diagnostic sample site, method, date Histology / cytology Largest tumour diameter (cm) Staging investigations and findings TNM edition

9th ed.: N2a/N2b, M1c1/M1c2.

c1-TNM before MDT

Biomarkers

PD-L1 (TPS, %) numeric only

TMB (mut/Mb)

MSI / MMR status

Molecular testing method

Molecular sample type Driver alterations (actionable)

Specify actionable subtypes.

EGFR

ALK fusion

ROS1 fusion

BRAF

KRAS

MET

RET fusions

ERBB2 / HER2

NTRK1 to 3 fusions

NRG1 fusion

Immunotherapy / resistance markers

STK11 / LKB1

KEAP1

SMARCA4

Other NGS findings

Patient preference

Patient's treatment preference, concerns, and information needs

MDT recommendation

MDT participants Further investigations recommended c2-TNM after MDT Treatment intent Surgery or bronchoscopic procedures lobectomy / segmentectomy, bronchoscopy, stents Oncological drug therapy neoadjuvant/perioperative IO, adjuvant osimertinib, consolidation durvalumab; trial eligibility Radiotherapy chemoradiation, SABR for early-stage/oligometastatic; target and fractionation Symptom care and supportive care